Recent 8-K filings for MYO

• May 7, 2026, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01 ◈ Earnings Releases

  Myomo Q1 revenue $10.1M (+3% YoY); net loss narrows to $3.0M; guides Q2 $10.3M-$10.8M

  Revenue $10.1M (+3% YoY), net loss $3.0M ($0.07/sh) vs $3.5M loss ($0.08/sh) in Q1 2025.

• March 9, 2026, 7:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01 ◈ Earnings Releases

  Myomo Q4 revenue falls 6% to $11.4M; net loss widens to $3.8M

  Q4 revenue $11.4M (-6% YoY); full year $40.9M (+26% YoY).

• November 10, 2025, 6:59 PM ET earnings materiality 0.70 neutral item 1.01item 2.02item 2.03item 3.02item 9.01 ◈ Debt Financings◈ Equity Issuances

  Myomo Q3 revenue $10.1M (+10% YoY); net loss $0.09/shr; FY guidance $40-42M

  Revenue $10.1M, up 10% YoY; 186 units sold (+16%), ASP ~$54,200 (-5%).

• August 11, 2025, 7:59 PM ET earnings materiality 0.85 negative item 2.02item 9.01

  Myomo Q2 revenue $9.7M (+28%) but operating loss widens; cuts FY2025 guidance to $40-42M

  Revenue $9.7M (+28% YoY), revenue units 178 (+13%), ASP ~$54,200 (+14%).

• June 18, 2025, 7:59 PM ET other material materiality 0.75 positive item 7.01item 9.01

  Myomo sets 2028 revenue target of $100M, gross margin 70-72% at Investor Day

  Aspirational goal of $100M annual revenue by 2028, including $15M international and $20M O&P channel revenue.

• May 7, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Myomo Q1 revenue $9.8M (+162%); record 700 pipeline adds; guides Q2 $9.0-9.5M

  Revenue $9.8M (+162% YoY) on 182 units (+100%); gross margin 67.2% (up 600 bps).

• April 10, 2025, 7:59 PM ET other material materiality 0.60 neutral item 4.01item 5.02item 7.01item 9.01 ◈ Auditor Changes ×2◈ executive_change ×2

  Myomo names CBIZ as new auditor; two directors exit board

  Marcum LLP resigned as auditor April 8; CBIZ CPAs engaged after acquiring Marcum's attest business.

• March 10, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Myomo Q4 revenue $12.1M record, first positive op. cash flow; guides FY2025 $50-53M

  Q4 revenue $12.1M (+154% YoY); 220 units shipped (+106%); ASP ~$54,900 (+23%).

• December 5, 2024, 6:59 PM ET other material materiality 0.70 neutral item 1.01item 8.01item 9.01

  Myomo prices $15M public offering of 3M shares at $5.00; underwriter option exercised in full

  3,000,000 shares priced at $5.00 each; gross proceeds of $15.0M expected before expenses.

• November 6, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Myomo Q3 revenue record $9.2M (+81% YoY); FY guidance raised to $30-31M

  Record Q3 product revenue $9.2M, +83% YoY; net loss $1.0M ($0.03/sh) vs $2.0M loss year ago.

• August 13, 2024, 7:59 PM ET other material materiality 0.75 positive item 1.01item 2.03item 9.01

  Myomo signs 88-month lease for 36,208 sq ft in Burlington, MA for HQ and manufacturing

  Lease for approx. 36,208 rentable sq ft at 45 Blue Sky Drive; monthly rent starts at $96,250 and escalates over 8-year term.

• August 6, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Myomo Q2 2024 revenue $7.5M (+77% product revenue); record 213 MyoPro orders

  Product revenue $7.5M (+77% YoY); total revenue $7.5M (+26% YoY) reflecting prior-year license fee.

• July 15, 2024, 7:59 PM ET debt materiality 0.65 neutral item 1.01item 2.03item 9.01

  Myomo enters $4M revolving credit facility with Silicon Valley Bank

  Revolver up to $4M (expandable to $5.5M); interest rate greater of 8.50% or prime + 0.50%.

• July 8, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Myomo expects record Q2 revenue $7.2M-$7.4M, up 92-97% sequentially

  Preliminary Q2 revenue $7.2M-$7.4M, 92-97% sequential increase, highest ever.

• May 8, 2024, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01 ◈ Earnings Releases

  Myomo Q1 revenue $3.8M (+9% YoY); backlog record 275 units; net loss $3.8M

  Revenue $3.8M (+9% YoY); product revenue $3.75M; revenue units 91 (+14%).

• May 6, 2024, 7:59 PM ET regulatory materiality 0.65 positive item 8.01item 9.01

  Myomo receives first lump sum Medicare reimbursements for MyoPro under new CMS fees

  CMS through DME MACs remitted lump sum reimbursements for MyoPros to Medicare Part B beneficiaries.

• March 7, 2024, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01 ◈ Earnings Releases

  Myomo Q4 revenue $4.8M (+18% YoY), backlog record 230 units, guides FY2024 rev $28M-$30M

  Q4 product revenue $4.756M (+18% YoY); recognized 107 MyoPro units (+6%).

• March 1, 2024, 6:59 PM ET regulatory materiality 0.70 positive item 8.01item 9.01

  CMS finalizes Medicare fee schedule for Myomo's MyoPro at $33,481-$65,872 per device

  CMS final fee schedule rates: L8701 (Motion W) $33,480.90, L8702 (Motion G) $65,871.74, effective April 1, 2024.

• January 17, 2024, 6:59 PM ET earnings materiality 0.80 positive item 1.01item 2.02item 8.01item 9.01 ◈ Earnings Releases◈ Material Agreements

  Myomo reports prelim Q4 revenue $4.6-$4.8M (+14-19% YoY), raises $6M in registered direct offering

  Preliminary Q4 2023 revenue expected $4.6-$4.8M, up 14-19% YoY; cash $8.7M at Dec 31, 2023.

• November 7, 2023, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01 ◈ Earnings Releases

  Myomo Q3 record product revenue $5.0M, up 27% YoY; net loss narrows to $2.0M

  Total revenue $5.1M (+28% YoY); product revenue $5.0M (+27%) on 119 units (+37%).

• November 6, 2023, 6:59 PM ET regulatory materiality 0.65 positive item 8.01item 9.01

  CMS proposes Medicare reimbursement rates for MyoPro: $31,745 for L8701, $62,457 for L8702

  CMS proposed fee schedule rates: L8701 (Motion W) at $31,745.42 and L8702 (Motion G) at $62,457.28.

• November 2, 2023, 7:59 PM ET regulatory materiality 0.75 positive item 8.01item 9.01

  CMS classifies MyoPro as Medicare Part B brace, lump-sum reimbursement from Jan 1, 2024

  CMS final rule published Nov 1, effective Jan 1, 2024: MyoPro classified as a brace, paid lump sum.

• August 28, 2023, 7:59 PM ET other material materiality 0.65 neutral item 1.01item 9.01

  Myomo raises $4.4M in registered public offering of common stock and pre-funded warrants

  Offering consists of 5,413,334 shares of common stock and 1,920,000 pre-funded warrants at $0.60 per share/$0.5999 per warrant.

• August 24, 2023, 7:59 PM ET regulatory materiality 0.75 positive item 1.02item 8.01item 9.01 ◈ Material Agreements

  Myomo receives first Medicare Part B payments for MyoPro; terminates Keystone stock agreement

  Received payment on two MyoPro claims under Medicare Part B capped rental program (13-month payout).

• August 9, 2023, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  Myomo Q2 revenue up 62% to $6.0M; net loss narrows to $1.0M

  Product revenue $4.2M (+15% YoY); revenue units 97 (+21%). Total revenue includes $1.7M JV license fee.

• May 10, 2023, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  Myomo Q1 product rev up 20% to $3.4M; record 438 pipeline patients added

  Product revenue $3.4M, +20% YoY; total revenue $3.4M (-11% due to prior-year license fee).

• April 10, 2023, 7:59 PM ET other material materiality 0.75 positive item 8.01item 9.01

  Myomo receives $1.7M final license fee from China JV, enabling MyoPro manufacturing and sales in China

  Received final $1.7M of initial license fee from Jiangxi Myomo JV; total upfront fee now $2.7M.

• March 13, 2023, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Myomo Q4 revenue flat at $4.0M; net loss improves to $0.29/share

  Q4 product revenue $4.0M, flat YoY and up 2% sequentially; 101 units (down 6% YoY).

• January 13, 2023, 6:59 PM ET other material materiality 0.60 neutral item 1.01item 9.01 ◈ Material Agreements ×2

  Myomo raises $6.5M in registered offering of 13.17M shares and pre-funded warrants at $0.325

  Gross proceeds of $6.5M from sale of 13,169,074 shares at $0.325 and pre-funded warrants for 6,830,926 shares at $0.3249.

• December 7, 2022, 6:59 PM ET other material materiality 0.65 negative item 8.01

  Myomo fails to convene special meeting to approve Keystone stock issuance; withdraws proposals

  Special meeting on Dec 7, 2022 lacked quorum; only majority of proxies received were in favor.

• November 10, 2022, 6:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01 ◈ Earnings Releases

  Myomo reports Q3 product revenue $4.0M, up 8% sequentially; record backlog of 184 units

  Product revenue $4.0M, down 9% YoY but up 8% sequentially; revenue units 87, down 15% YoY.

• September 27, 2022, 7:59 PM ET regulatory materiality 0.65 negative item 8.01

  CMS defers Myomo's request to reclassify MyoPro as brace; decision expected Q1 2023

  CMS declined to rule on Myomo's request to reclassify MyoPro from rental DME to lump-sum brace.

• August 3, 2022, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Myomo Q2 revenue up 18% to $3.7M; record pipeline adds 52% YoY; net loss widens to $0.42/share

  Revenue $3.7M (+18% YoY, +28% seq); product units 80, flat YoY; ASP up via direct billing (83% of revenue).

• July 7, 2022, 7:59 PM ET earnings materiality 0.70 positive item 8.01item 9.01

  Myomo pre-announces Q2 revenue $3.4-3.6M, up 10-16% YoY; record pipeline adds

  Preliminary Q2 2022 revenue $3.4–$3.6M, up 10–16% vs Q2 2021; all product revenue.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.68 · Most common event earnings

21 positive 4 negative 25 neutral

source · MYO on sec.gov